SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

10359	Companies
215666	Keywords
145448	Articles
114230	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 09/20/2024 at 11:30, 1 year 7 months ago

CP : Le tolebrutinib a permis d’allonger de 31 % le délai avant progression confirmée du handicap dans le cadre d’une étude de phase III menée chez des personnes présentant une sclérose en plaques secondairement progressive non active
Le tolebrutinib allonge de 31 % le délai avant progression du handicap dans une étude de phase III sur la sclérose en plaques. Les résultats ont été présentés au Congrès de l’ECTRIMS

Sclérose En Plaques Étude De Phase III ECTRIMS Tolebrutinib Handicap
BRIEF

published on 09/16/2024 at 18:49, 1 year 7 months ago

Sanofi Reports Share and Voting Rights Data for August 2024

Voting Rights Shares Investor Relations Sanofi August 2024
BRIEF

published on 09/16/2024 at 18:49, 1 year 7 months ago

Sanofi publie ses données sur les actions et les droits de vote pour août 2024

Actions Droit De Vote Relations Avec Les Investisseurs Sanofi Août 2024
PRESS RELEASE

published on 09/16/2024 at 18:44, 1 year 7 months ago

Sanofi: Information concerning the total number of voting rights and shares - August 2024
Sanofi discloses total number of voting rights and shares as per French Commercial Code and AMF regulations

Voting Rights French Commercial Code Shares AMF Regulations Sanofi
PRESS RELEASE

published on 09/16/2024 at 18:44, 1 year 7 months ago

Sanofi: Informations relatives au nombre de droits de vote et d'actions - AOUT 2024
Annonce des droits de vote et d'actions de Sanofi conformément au Code de commerce et au Règlement de l'AMF

Droits De Vote Code De Commerce Actions AMF Sanofi
BRIEF

published on 09/11/2024 at 07:10, 1 year 7 months ago

Dupixent Phase 3 Study Shows Promise for CSU Patients

Sanofi Phase 3 Dupixent CSU Regeneron
BRIEF

published on 09/11/2024 at 07:10, 1 year 7 months ago

L'étude de phase 3 sur Dupixent se révèle prometteuse pour les patients atteints de CSU

Sanofi Phase 3 Dupixent CSU Regeneron
PRESS RELEASE

published on 09/11/2024 at 07:05, 1 year 7 months ago

Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU. Positive pivotal data support Dupixent as a new targeted therapy for CSU

Phase 3 Study Dupixent CSU Chronic Spontaneous Urticaria Itch And Hives
PRESS RELEASE

published on 09/11/2024 at 07:05, 1 year 7 months ago

Communiqué de presse : Dupixent : améliorations significatives du prurit et de l’urticaire confirmées par une étude de phase III chez des patients présentant une urticaire chronique spontanée
Dupixent : résultats positifs de l'étude de phase III confirmant l'efficacité du traitement de l'urticaire chronique spontanée non contrôlée. Nouvelle soumission réglementaire aux États-Unis

Traitement Dupixent Étude De Phase III Résultats Positifs Urticaire Chronique Spontanée
BRIEF

published on 09/11/2024 at 07:05, 1 year 7 months ago

Dupixent Demonstrates Significant Efficacy in Bullous Pemphigoid

Clinical Trial Sanofi Dupixent Bullous Pemphigoid Disease Remission

Accesswire

Published on 05/07/2026 at 05:40, 3 hours 23 minutes ago

New Horizon Aircraft Ltd. Announces Pricing of $20 Million Offering of Common Shares
Published on 05/07/2026 at 02:00, 7 hours 3 minutes ago

Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York
Published on 05/06/2026 at 23:30, 9 hours 33 minutes ago

Stabilis Solutions Announces First Quarter 2026 Results
Published on 05/06/2026 at 23:05, 9 hours 58 minutes ago

Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
Published on 05/06/2026 at 23:00, 10 hours 3 minutes ago

Green Bridge Metals Strengthens Technical and Strategic Team as 2026 Work Programs Advance

View all ACCESSWIRE

EQS Group

Published on 05/07/2026 at 08:48, 15 minutes ago

Finnvera’s Annual General Meeting: New members to Finnvera’s Board of Directors and Supervisory Board
Published on 05/07/2026 at 08:36, 27 minutes ago

Cherry SE publishes results for the first quarter of 2026 – Operating profitability significantly improved
Published on 05/07/2026 at 08:30, 32 minutes ago

15 Years Delivering to You
Published on 05/07/2026 at 08:30, 32 minutes ago

L'UE mise sur une politique climatique axée sur le marché: allègement des péages et des normes CO₂ pour les poids lourds
Published on 05/07/2026 at 08:30, 33 minutes ago

Restoration: Grand Vision Media Holdings PLC

Les Echos

Published on 05/07/2026 at 07:43, 1 hour 19 minutes ago

ENGIE - Q1 2026 financial information
Published on 05/07/2026 at 07:43, 1 hour 19 minutes ago

ENGIE - Information Financière 1er trimestre 2026
Published on 05/06/2026 at 18:00, 15 hours 3 minutes ago

Mise à disposition des documents relatifs à l'AG du 4 juin 2026
Published on 05/06/2026 at 18:00, 15 hours 3 minutes ago

Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026
Published on 05/06/2026 at 18:00, 15 hours 3 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of April 30, 2026

View all LES ECHOS COMFI WIRE